ursodeoxycholic acid has been researched along with 2019 Novel Coronavirus Disease in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 12 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cruz Parada, E; Hernández-Huerta, MT; Martínez Cruz, M; Matias-Cervantes, CA; Pérez-Campos Mayoral, E; Pérez-Campos Mayoral, L; Pérez-Campos, E; Ramos-Martínez, EG; Rodal Canales, FJ; Romero Díaz, C; Sánchez Navarro, LM; Zenteno, E | 1 |
| Hamaguchi, T; Hirayama, M; Ito, M; Kashihara, K; Maeda, T; Nishiwaki, H; Ohno, K; Tsuboi, Y; Ueyama, J | 1 |
| Bettinger, D; Bounidane, A; Finkelmeier, F; Fitting, D; Groba, SR; Hamesch, K; Hollenbach, M; Hunyady, P; Kirstein, MM; Kluwe, J; Kütting, F; Marquardt, JU; Mücke, MM; Mücke, VT; Peiffer, KH; Rüther, DF; Schlevogt, B; Sekandarzad, A; Streller, L; Waidmann, O; Weiss, F; Wengenmayer, T; Zeuzem, S | 1 |
| Baker, S; Bargehr, J; Barnes, E; Barritt, AS; Bastaich, DR; Box, H; Bramwell, C; Brevini, T; Brown, ML; Brown, S; Buczacki, SJA; Buescher, G; Butler, AJ; Clements, D; Corbett, G; Cox, H; Crozier, TWM; Curley, P; Dahman, B; Darvish-Damavandi, M; Davenport, AP; Davies, SE; Dillon, S; Dougan, G; Fear, C; Ferreira, RD; Fisher, AJ; Forrest, S; Fuchs, CD; Galanakis, V; Gelson, WTH; Gibbs, P; Gorgoulis, VG; Griffiths, C; Gupta, RK; Hagström, H; Herriott, J; Heslop, JA; Humphreys, P; Illingworth, CJR; John, BV; Kijak, E; Kuc, RE; Lee, JH; Lohse, AW; Maes, M; Marjot, T; Matheson, NJ; Mells, GF; Melum, E; Mlcochova, P; Moon, AM; Mulcahy, VL; Muraro, D; Neary, M; Owen, A; Pereyra-Gerber, P; Pertinez, H; Rossetti, D; Saeb-Parsy, K; Sampaziotis, F; Scott, WE; Sharp, J; Sinha, S; Stewart, J; Swift, L; Tatham, L; Trauner, M; Tysoe, OC; Upponi, SS; Valentijn, A; Vallier, L; Varankar, SS; Vila-Gonzalez, M; Wang, L; Watson, CJE; Webb, GJ; Wester, A; Williams, TL | 1 |
| Bhat, M; Prayitno, K | 1 |
| Huang, Y; Li, Z; Lu, H; Wu, Y; Xu, Q; Zeng, Y | 1 |
| Bastaich, D; Brevini, T; Chao, HH; Chin, AM; Dahman, B; Deng, Y; Ferreira, RD; John, BV; Kaplan, DE; Mahmud, N; Moon, A; Sampaziotis, F; Serper, M; Taddei, TH; Webb, G | 1 |
| Cui, X; Li, X; Li, Y; Lin, Y; Zhu, N | 1 |
| Distrutti, E; Fiorucci, S; Urbani, G | 1 |
| Liu, T; Wang, JS | 1 |
| Aghemo, A; Aliberti, S; Angelotti, G; Bartoletti, M; Calatroni, M; Carella, F; Cecconi, M; Ciccarelli, M; Colapietro, F; De Nicola, S; Desai, A; Lleo, A; Masetti, C; Omodei, P; Ormas, M; Pugliese, N; Reggiani, F; Shiffer, D; Voza, A | 1 |
| Abdulrab, S; Al-Maweri, S; Halboub, E | 1 |
12 other study(ies) available for ursodeoxycholic acid and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Interaction of Spike protein and lipid membrane of SARS-CoV-2 with Ursodeoxycholic acid, an in-silico analysis.
Topics: Antiviral Agents; COVID-19; Drug Repositioning; Humans; Hydrogen Bonding; Lipid Bilayers; Membrane Fusion; Molecular Docking Simulation; Molecular Dynamics Simulation; Phospholipids; Protein Binding; Protein Conformation, alpha-Helical; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Ursodeoxycholic Acid; Virion | 2021 |
Intestinal Collinsella may mitigate infection and exacerbation of COVID-19 by producing ursodeoxycholate.
Topics: Actinobacteria; COVID-19; Gastrointestinal Microbiome; Humans; Intestines; SARS-CoV-2; Ursodeoxycholic Acid | 2021 |
Secondary Sclerosing Cholangitis Following Coronavirus Disease 2019 (COVID-19): A Multicenter Retrospective Study.
Topics: Cholangitis, Sclerosing; COVID-19; COVID-19 Testing; Humans; Retrospective Studies; Risk Factors; Ursodeoxycholic Acid | 2023 |
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2.
Topics: Angiotensin-Converting Enzyme 2; Animals; COVID-19; COVID-19 Drug Treatment; Cricetinae; Humans; Liver; Liver Transplantation; Lung; Mice; Nasal Mucosa; Organoids; Receptors, Virus; Registries; Reproducibility of Results; Retrospective Studies; SARS-CoV-2; Transcription, Genetic; Ursodeoxycholic Acid | 2023 |
Repurposing UDCA, an FXR Inhibitor, to Prevent SARS-Cov-2 Infection.
Topics: Antiviral Agents; COVID-19; Drug Repositioning; Humans; Molecular Docking Simulation; SARS-CoV-2; Transcription Factors; Ursodeoxycholic Acid | 2023 |
Development of HPLC-CAD method for simultaneous quantification of nine related substances in ursodeoxycholic acid and identification of two unknown impurities by HPLC-Q-TOF-MS.
Topics: Chromatography, High Pressure Liquid; COVID-19; Drug Contamination; Humans; Respiratory Aerosols and Droplets; SARS-CoV-2; Ursodeoxycholic Acid | 2023 |
Ursodeoxycholic acid is associated with a reduction in SARS-CoV-2 infection and reduced severity of COVID-19 in patients with cirrhosis.
Topics: COVID-19; Humans; Liver Cirrhosis; Liver Cirrhosis, Biliary; Retrospective Studies; SARS-CoV-2; Ursodeoxycholic Acid | 2023 |
Protective effect of ursodeoxycholic acid on COVID-19 in patients with chronic liver disease.
Topics: Cholagogues and Choleretics; COVID-19; COVID-19 Vaccines; Humans; Liver Diseases; SARS-CoV-2; Ursodeoxycholic Acid | 2023 |
Bile Acids and SARS-CoV-2: Ursodeoxycholic Acid as a Potential Treatment of COVID-19.
Topics: Bile Acids and Salts; COVID-19; Deoxycholic Acid; Humans; SARS-CoV-2; Ursodeoxycholic Acid | 2023 |
Ursodeoxycholic acid administration did not reduce susceptibility to SARS-CoV-2 infection in children.
Topics: Child; COVID-19; Hospitalization; Humans; Liver Diseases; SARS-CoV-2; Ursodeoxycholic Acid | 2023 |
Ursodeoxycholic Acid Does Not Improve COVID-19 Outcome in Hospitalized Patients.
Topics: COVID-19; Diabetes Mellitus, Type 2; Humans; SARS-CoV-2; Ursodeoxycholic Acid; Vaccination | 2023 |
Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.
Topics: Anti-Inflammatory Agents; Apoptosis; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokine Release Syndrome; Humans; Models, Theoretical; Pandemics; Pneumonia, Viral; SARS-CoV-2; Ursodeoxycholic Acid | 2020 |